On January 27, 2022, the FDA announced its decision to not include Glycopyrrolate on the 503B bulks list. Following this announcement, outsourcing facilities will not be permitted to compound the drug-using bulk API, unless the product appears in the future…
In our ongoing effort to enhance our customers’ experience, SCA Pharma has responded to feedback and made several changes to the customer portal. Here are recent updates: On the home page, customers will find previously published communications, providing easy access…
WINDSOR, CONN. (Jan. 28, 2021)– SCA Pharmaceuticals, LLC, announced details last week of their acquisition by The Vistria Group and Excellere. Continuing their strategic growth initiatives, SCA Pharma is announcing the appointment of Mr. Scott Luce as Chief Commercial Officer. …
WINDSOR, CONN. (Jan. 21, 2021) – SCA Pharmaceuticals, LLC (“SCA Pharma”), has entered into a definitive membership interest purchase agreement with The Vistria Group (“Vistria”) and Excellere Partners (“Excellere”). The Vistria Group and Excellere Partners have purchased all of the…
SCA Pharma just wrapped up the Health Connect Partners (HCP) Hospital Pharmacy fall virtual conference, where we shared a new virtual tour of the SCA Pharma facilities. The tour highlights the steps throughout the product journey, from receiving materials to…
October is National Medicine Abuse Awareness Month, an annual effort by the Community Anti-Drug Coalitions of America to raise awareness of the dangers of prescription and over-the-counter medicine abuse. And SCA Pharma is partnering with hospital pharmacies to better control…